Entities

Develops reversible male contraceptives. Its pipeline includes NES/T, an investigational daily topical hormonal gel designed to suppress sperm production, and ADAM, an investigational long-lasting non-hormonal implant. The company is advancing NES/T toward Phase 3 development following a completed Phase 2b study.

Invests in and helps build biotechnology and medical-device companies across North America. The firm supports life sciences businesses at multiple stages, including companies developing medicines for neurological disease, oncology and other serious conditions, and technologies that improve diagnosis and treatment. Its partners work from Toronto, Montréal, Vancouver and Boston. The firm adopted the Lumira name following a management buyout of MDS Capital in 2007.

Develops precision sodium-channel medicines for neurological disorders, initially focusing on genetic epilepsies and chronic neuropathic pain. Its NaViGATion discovery platform combines AI-enabled chemistry, structural biology, human disease biology and ion-channel expertise to find compounds that selectively modulate disease-related neuronal firing.

Develops a handheld histotripsy device that uses focused ultrasound to mechanically destroy tumors and other targeted tissue without incisions, ionizing radiation or thermal damage. Its ultrasound-guided platform is intended to make non-invasive ablation available across more clinical settings and remains investigational.

Martin J. Emerson is President and Chief Executive Officer at Monteris Medical. Known as Marty Emerson, he has led the company since 2016 and also serves on its board.

Joined the Charles River board in May 2025. Led ImmunoGen from 2016 until its acquisition by AbbVie in 2024 and previously worked at Shire and Genzyme.

Astellas Pharma Inc. is a Tokyo-based global life sciences company listed on the Tokyo Stock Exchange (4503). It develops and commercializes therapies in oncology, ophthalmology, urology, immunology and women’s health, and advances drug discovery through genetic regulation, regenerative medicine and other biological platforms. Its Astellas Gene Therapies center develops AAV genetic medicines for rare diseases affecting the eye, central nervous system and neuromuscular system. The company also pursues digital and technology-enabled healthcare through its Rx+ activities. In October2024, Astellas Pharma committed a USD20million equity investment in neurodegenerative gene therapy developer AviadoBio alongside a separate option and license agreement for investigational AVB-101. The operating pharmaceutical company is the named investor in that agreement.

Develops medicines that restore mitochondrial quality by inducing mitophagy, the process that removes and replaces damaged mitochondria. Its research includes small molecules, peptides and nanoparticles designed to activate clearance pathways and address mitochondrial dysfunction associated with disease and aging.

Develops therapies for gout, focusing on patients whose uric acid levels and symptoms are inadequately controlled by current treatments. Its lead investigational medicine, dotinurad, is an oral selective URAT1 inhibitor intended to reduce uric acid reabsorption in the kidneys. The company is conducting Phase 3 registration trials and a Phase 2 study for difficult-to-treat gout.

Develops therapies for cardiometabolic diseases by targeting the heart’s energy metabolism. Its lead candidate, ninerafaxstat, is designed to improve myocardial energy efficiency by shifting energy production from fatty acids toward glucose oxidation, with clinical development focused on non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.

Develops therapies for pulmonary arterial hypertension, a disease involving high blood pressure in the arteries connecting the heart and lungs. Its approach builds on vascular-physiology research from Japan’s National Cerebral and Cardiovascular Center. The clinical-stage company was incubated at RA Capital’s Raven incubator.

Develops oral small-molecule medicines for neurological and neuropsychiatric disorders. Its clinical-stage pipeline includes compounds licensed from Eisai and Hansoh for conditions such as focal epilepsy, schizophrenia, tinnitus and reversible encephalopathy. The company is advancing lead candidates through Phase 2 development and announced USD106 million in combined seed and Series A financing in April 2026; the individual round amounts were not disclosed.

Develops genetic medicines using an RNA-based platform that inserts whole therapeutic genes at a specific genomic site without viral vectors or double-strand DNA breaks. It uses lipid nanoparticles to deliver RNA, with programs for in vivo CAR-T cell engineering and liver-directed gene insertion targeting cancer, autoimmune disease and severe genetic disorders.

Albert Kim holds the source-published role of Advisor within RA Capital Management’s Raven group. Published academic qualifications: MD , PhD. Universities identified in the own biography: Harvard University, University of California Los Angeles. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Andrew Levin holds the source-published role of Advisor within RA Capital Management’s Healthcare group. The individual directory reports joining in2026; a precise appointment day is not available. Published academic qualifications: MD , PhD. Universities identified in the own biography: Princeton University, Massachusetts Institute of Technology, Harvard Medical School. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Barry Greene serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

ArrePath board member and Insight Partners managing director focused on computational biology. Previously a CRV general partner and investor at Innovation Endeavors, and co-founded Integrated Plasmonics. Studied computer science at Harvard and conducted graduate research in biochemistry and molecular biophysics at Caltech. Insight Partners source, reviewed October 8, 2026: I believe in remote human possibilities and the almost infinite potential of the individual. To me, it’s clear that people matter most of all. I’ve always wanted to understand how the mind works. In college, I studied computational neuroscience, worked in a primate cognition lab, and graduated with a degree in computer science. My first real job was writing software to simulate computer networks. It was amazing to me how well simulation works, that you can create a faithful representation of a system, simulate its dynamics, and learn meaningful things about the real live system. If this works so well for computer networks (and bridges, airplanes, autonomous vehicles, etc.), why shouldn’t it work for biology? This question and the desire to simulate biological systems led me to Caltech, where I enrolled in a biophysics PhD program. I worked in an early cryo-EM lab where we looked at the simplest cells in 3D. I built computational models to simulate tiny pieces of these cells. The work was fascinating but disconnected from the realities of the human condition. Academic science is slow and careful. While professors compete for limited resources, people are dying. I began to realize the best way for me to have an impact and help people is to accelerate biomedical innovation. My desire to make the future happen faster is how I discovered startups. Shortly after, I left grad school (with some papers, but no degree) and started a biosensor company with a couple of friends. We raised funding from great investors and hired the most talented scientists and engineers, however we ultimately failed. Democratizing diagnostics is a worthwhile mission, but a challenging business. From there, I found my way into investing and it’s a perfect fit. Backing brilliant founders who are innovating at the forefront of biomedicine feels like a force multiplier for good. I began my venture career at Innovation Endeavors, investing at the intersection of data science and life science. After that, I worked at CRV and helped build the firm’s bioengineering practice. I came to Insight in July 2021 to lead our emerging efforts in the bio space. My team and I love technology-enabled approaches to drug discovery and development, new therapeutic modalities, and especially curative therapies. Bring us your wildest ideas but show us how you will reduce them to practice. We’re here and ready to listen.

Jenna Hebert holds the source-published role of Investment Director within RA Capital Management’s Healthcare group. The individual directory reports joining in2021; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: University of Pennsylvania, University of Oxford. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Biotechnology company builder and chemist formerly leading Peloton Therapeutics, with earlier discovery-chemistry experience at Array BioPharma.

John Maraganore serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. He also advises Magnetic Ventures, according to its current team directory. John Maraganore joined Takeda’s board as an external director in June 2022. He previously led Alnylam and held strategic development leadership at Millennium Pharmaceuticals. His current professional roles include JMM Innovations and Corsera Health, alongside biotechnology boards and advisory work. John Maraganore became an Omega Advisor and Venture Partner in September 2022. He was founding Chief Executive Officer of Alnylam from 2002 to 2021, following roles at Millennium, Biogen, ZymoGenetics and Upjohn. His scientific degrees include a University of Chicago doctorate.

Ken joined Venture Investments (US) Inc. in San Francisco, California in 2015. Ken brings experience as a Senior Market Planning Manager at Genentech, where he helped guide strategic decision making for the Ophthalmology and HER2 franchises. Prior to Genentech, Ken worked as a management consultant at L.E.K. Consulting and as the Entrepreneurship Program Manager at QB3/Mission Bay Capital, where he helped create new programs to launch and support life sciences companies in the Bay Area. Ken studied cellular lipid storage and metabolism as an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes, earned a PhD in Pharmacology from Yale University, and has a BS in Molecular Biology from Texas Tech University, where he was a Howard Hughes Medical Institute undergraduate research fellow.

Laura Tadvalkar is currently a Managing Director on the Venture Team at RA Capital Management, which she joined in 2020. RA Capital’s own biography confirms her prior Principal role at MP Healthcare Venture Management and earlier consulting at Clarion Healthcare. She completed her Kauffman fellowship at MPH with Jeffrey Moore and Naoya Sato as mentors. Her RA Capital interview describes supporting an MPH portfolio company’s business-development work. She holds a BS in Chemistry from Yale and a PhD in Chemical Biology from Harvard. Her MPH role is historical; the current RA role, portrait and personal financial attributions are preserved. Current source-verified RA affiliation: Laura Tadvalkar holds the source-published role of Managing Director, Venture within RA Capital Management’s Healthcare group. The individual directory reports joining in2020; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: Yale University, Harvard University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Matt Stanton holds the source-published role of Advisor within RA Capital Management’s Raven group. Published academic qualifications: PhD, BS. Universities identified in the own biography: University of North Carolina at Chapel Hill, Virginia Technical University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Mikael Dolsten is published by Arbor Biotechnologies as Board Member. Arbor lists this professional background: Former Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer, Inc..

Paul B. Rothman, M. D. Director, Chair of the Quality and Compliance Committee Paul B. Rothman has served as a director of the Company since June 6, 2023 and as Chairman of the Quality and Compliance Committee since June 2024. Dr. Rothman, a rheumatologist and molecular immunologist, was previously the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr. Rothman held various leadership positions at Columbia University and the University of Iowa. Dr. Rothman currently serves on the board of directors of Merck and Co. and the King Faisal Specialist Hospital and Research Center in Saudi Arabia. In addition, he consults for several investment firms including RA Capital, Mingxin Capital Growth Fund and ANV Management. Dr. Rothman holds a Bachelor of Science degree in biology from the Massachusetts Institute of Technology and an M.D. from Yale University, and is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Association for the Advancement of Sciences, the American Society for Clinical Investigation, and the Association of American Physicians. Current source-verified RA affiliation: Paul Rothman holds the source-published role of Venture Partner within RA Capital Management’s Raven group. The individual directory reports joining in2025; a precise appointment day is not available. Published academic qualifications: MD. Universities identified in the own biography: Massachusetts Institute of Technology, Yale University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Nimbus Therapeutics director with biotechnology venture investment, drug development and business experience at SR One, GSK, Genentech and Bio-Rad Laboratories.

Deep Track Capital managing director and Draig Therapeutics board observer. Also serves on Imbria Pharmaceuticals' board and has healthcare investment experience at New Leaf Venture Partners.

Seth Fischer is listed by HealthQuest Capital as Industry Advisory Board Member. The directory describes their outside context as Former Company Group Chairman Johnson & Johnson; this is not an executive title at HealthQuest. The primary biography explicitly identifies Seth H. Z. Fischer, the Johnson & Johnson veteran and Catalys Pacific partner, distinct from Oasis founder Seth Fischer.

Timothy (Tim) Walbert is a senior adviser to Patient Square Capital, managing partner of HRZN Partners and adviser to Amgen. He previously led Horizon Therapeutics and IDM Pharma and serves as independent board chair of Crystalys Therapeutics.

Invests in and helps create biotechnology companies that bring Japanese scientific discoveries to global markets. Based in Tokyo and San Francisco, the firm connects Japanese academic and pharmaceutical research with the US startup ecosystem and finances companies from pre-seed through advanced clinical development across therapeutic modalities and disease areas, including neuroscience.

Dementia Discovery Fund partner with prior pharmaceutical business development experience; helped establish the fund and serves on boards of its biotechnology portfolio companies. Laurence Barker is a TRIMTECH non-executive director and SV Health Investors partner focused on the Dementia Discovery Fund. Before joining SV in 2016, he managed venture investments and licensing within GSK business development and worked at biotechnology companies.

AviadoBio is a London-based clinical-stage gene therapy company founded in 2019 from research at King’s College London and the UK Dementia Research Institute. It develops targeted AAV genetic medicines for neurodegenerative and retinal diseases, combining precision delivery, gene supplementation, optogenetics and its vMiX RNA interference gene-silencing platform. Its pipeline includes investigational AVB-101 for frontotemporal dementia with GRN mutations and preclinical AVB-406 targeting MAPT/tau for Alzheimer’s disease and other tauopathies. Its research and development focus also includes retinitis pigmentosa and other retinal dystrophies. Astellas made a strategic equity investment alongside an option and license agreement for AVB-101 in 2024. These are development programs; reported preclinical results and clinical trial authorizations do not establish approved clinical efficacy.

Provides automated backup monitoring, reporting and compliance software for managed service providers and IT teams. It consolidates backup results across vendors, identifies failures and missing jobs, creates actionable alerts and helps demonstrate that client data is protected. ScalePad acquired Backup Radar in November 2021 and continues to offer it within its MSP platform.

Provides cybersecurity governance, risk and compliance automation for managed service providers. Its software maps customer programs to frameworks such as SOC 2, ISO 27001 and CMMC, gathers compliance evidence through integrations, tracks risks and helps MSPs manage audits and recurring compliance services. ScalePad acquired ControlMap in March 2023 and continues to offer the platform.

Developed digital-work analytics software that helps teams understand how they use workplace applications, identify interruptions and fragmented workflows and improve productivity and software adoption. ScalePad acquired Produce8 in January 2026 to integrate software-usage insight into its MSP platform, supporting licensing, cost, risk and AI-adoption decisions.

Provides cloud quote-to-cash software for managed service providers and other technology businesses. It automates product catalogs, proposal creation, approvals, contracts and payments to reduce quoting errors and speed up sales. ScalePad acquired Quoter in October 2023 and offers it as part of its MSP platform.

Provides training, onboarding and team-development software for managed service providers. Its platform combines role-specific learning, repeatable onboarding processes and accountability tools to help MSPs develop staff and improve service, sales and customer-management operations. The company describes itself as self-funded.

Builds a Microsoft 365 management and security platform for managed service providers. It lets MSPs apply and maintain shared policy baselines across customer tenants, assess configurations, back up and restore policies, manage Intune applications, detect and respond to threats and prepare customers to use Microsoft Copilot.

Publishes research, articles, guides, workshops and books that help managed service providers grow their businesses. Its content covers marketing, sales, financial management and service operations, alongside growth strategy and coaching. Top Down Ventures acquired the publishing platform in May 2025.

Provides software for managed service providers to manage customer IT assets, hardware warranties and renewals, compliance programs, backup monitoring, business intelligence and quote-to-cash workflows. Its connected platform helps MSPs assess client environments, plan technology investments, document service outcomes and sell and deliver ongoing IT services.

SV Health Investors operating partner and Pheno Therapeutics non-executive director; molecular biologist with research leadership experience at Repertoire, Bioverativ and Biogen.

Pheno Therapeutics is an Edinburgh-based clinical-stage biotechnology company spun out from the University of Edinburgh, developing small-molecule therapies for neurodegenerative and demyelinating disorders. It targets oligodendrocyte biology and GPR17 antagonism to promote the nervous system’s natural remyelination processes, initially focusing on multiple sclerosis. Its investigational lead candidate PTD802 was licensed from UCB; UK clinical-trial authorisation in January2025 and US FDA IND clearance in June2026 enable first-in-human safety and tolerability studies. The company combines human phenotypic screening, stem-cell technology and myelin biology; clinical efficacy remains to be established.

Automates billing, accounts receivable and payment collection for managed service providers and other invoice-driven businesses. It connects accounting, payment-processing and service-management systems to deliver invoices, follow up on collections, accept card and bank payments and reconcile transactions.

Provides cyber-risk intelligence and financial protection for managed service providers and their customers. Its Cork Vantage platform integrates security-tool data to identify vulnerabilities and misconfigurations, while Cork Protect supplements cyber insurance with financial relief for immediate incident-response costs, deductibles and certain cyber losses.

Builds AI software to automate back-office operations for startups and small businesses. Its platform connects financial records, contracts, payroll, equity information and other company data into a shared business model, supporting finance, board and investor reporting, compliance and people operations.

Provides digital risk protection for brands and security teams. Its platform monitors the open, deep and dark web for impersonation, leaked credentials, fraudulent domains and exposed third parties, using AI-assisted analysis and human validation to prioritize threats and support takedowns.

Develops AI agents that diagnose and resolve IT incidents and service requests for managed service providers and internal IT teams. The agents use device and environment information, company-specific knowledge and controlled access to IT tools to carry out routine support work, verify fixes and escalate uncertain or higher-risk actions to people.

Provides cybersecurity assessment and risk-validation software for managed service providers. Its platform discovers exposed assets, scans vulnerabilities, runs automated penetration tests and checks cloud configurations to identify exploitable risks, prioritize remediation and produce customer security reports.

Developed AI agents that automate high-volume IT service-desk operations for managed service providers, including ticket triage, classification and routine issue resolution. The software learns from historical tickets and workflows. ConnectWise acquired the company in January 2026 and is incorporating the technology into its IT-service platform.

Fountain Healthcare Partners is a life-sciences venture capital investor based in Dublin and New York. It backs seed and early-stage companies in Europe and the United States across specialty pharmaceuticals, biopharmaceuticals, medical devices and diagnostics, and typically leads or co-leads syndicates. Its relevant neuroscience and medical-technology holdings include Exciva, Neuromod Devices, Mainstay Medical and Medical Microinstruments; its published portfolio also records historical exits and companies that ceased operations. The firm reports over EUR425 million under management across its funds.

Jeffrey Cummings chairs ALZpath’s Scientific Advisory Board and leads the Chambers-Grundy Center for Transformative Neuroscience at UNLV. His work focuses on Alzheimer’s disease, clinical trials and drug development.

Vikram Sudarsan serves as President and Chief Executive Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

Duc brings over 25 years of drug development experience spanning a broad range of therapeutic areas, including cardiovascular, anti-infective, urology, epigenetics, CNS, reproductive medicine, autoimmune diseases, and oncology. His experience covers the full drug development continuum, from lead optimization through pivotal Phase III clinical development stages. Duc has built this expertise through senior roles in both large pharmaceutical companies, including Sanofi-Aventis, Pfizer, and Lundbeck, and innovative biotech companies such as Preglem (acquired by Gedeon Richter), Arisgen, EspeRare, Prexton Therapeutics (acquired by Lundbeck), Calypso Biotech (acquired by Novartis) and Step Pharma. He has successfully advanced multiple programs from early development through clinical development. Duc graduated from the French Grandes Écoles d’ingénieurs ESPCI with training in Physics, Chemistry, and Biology. He also holds an MSc in organic and bio-organic chemistry from Université Paris VI. ‍

Provides a platform and operating playbook for managed service providers to sell and deliver AI advisory and implementation services. Its tools assess customer readiness, discover unapproved AI use, plan adoption, manage Microsoft Copilot environments and track ongoing adoption and business outcomes.

Builds AI-assisted IT documentation and knowledge-management software for managed service providers. It captures and maintains information about assets, procedures and credentials, connects to MSP tools and supplies contextual answers through its Ask Lex assistant, helping service teams reduce documentation drift and handoff delays.

Provides AI governance and security software for managed service providers. Its tools discover employees’ AI usage, assess risk, enforce customer policies and help IT providers manage AI adoption across multiple client organizations.

Builds AI agents that automate IT service-desk work for managed service providers. Neo integrates with ticketing, remote monitoring, documentation and Microsoft 365 systems to triage requests, resolve routine issues, onboard users and perform scheduled checks, with configurable approvals and activity records.

Builds AI infrastructure that managed service providers can deploy under their own brands across multiple customer environments. Its platform includes an AI workspace, task agents, agent-building tools and centralized client management, helping IT providers govern AI services and turn them into recurring revenue.

Invests in and helps build software and AI companies serving managed service providers. Its venture-studio approach pairs early-stage capital with product, go-to-market, legal, finance and talent support. Founders Fund I backs companies automating IT service delivery, AI adoption, cybersecurity, documentation and related MSP workflows.

Provides cyber-insurance distribution and risk services for insurance agencies and managed service providers. It combines licensed cyber specialists, a Command Center platform and its Cornelius AI tools to assess exposure, prioritize customer outreach and help partners place coverage and manage cyber claims.

CARMA FUND is a Munich- and Frankfurt-based early-stage life-science and healthcare investor managed by CARMA FUND Management GmbH. Initiated with Ascenion and academic technology-transfer partners, it backs therapeutics, diagnostics, medical devices, digital health and research technologies in Europe. Its long fund term and flexible investment structures support academic spin-offs and extended biomedical development timelines. Relevant holdings include AI-powered pathology company Aignostics and neuroscience companies CereGate and Elkedonia. The manager reports EUR 56 million under management for CARMA FUND I.

Martin Müller is a Senior Investment Manager at CARMA FUND, joining in October 2023. With a medical background, he conducted cardiac imaging research at Leipzig Heart Center and Harvard Medical School, trained in radiology, and later worked in strategy consulting, private equity advisory and Philips Ventures.

Develops automated chemical-analysis technology to accelerate drug discovery and development. Breakout Ventures lists the company in its science-focused portfolio; its public website describes its approach as atomic physical intelligence.

Develops microalgal strains and precision-fermentation processes to manufacture high-value fats, oils and materials. Its current focus is supplying food, nutrition and wellness partners with differentiated lipid ingredients, including nutritional oils, bioactive fatty acids and alternatives to tropical fats; its technology has also been used in performance materials.

Uses fungal mycelium to grow materials and food ingredients. Its processes turn biological feedstocks into compostable packaging, foams and textile-like materials, while its AirMycelium platform supports whole-cut mycelium products and production on mushroom farms. Its food spinout MyForest Foods commercializes mycelium-based meat alternatives such as MyBacon.

General Sense, formerly Canaery, is a neurotechnology company developing a chemical-sensing platform by combining biological olfaction with neural interfaces and machine learning. Its Nose-Computer Interface reads neural signals at animals' olfactory bulbs and translates scent-related activity into digital data for identification and analysis. The current platform focuses on canine detection for security and defense, with potential applications in environmental monitoring, agriculture and medical diagnostics. Health-monitoring and diagnostic applications remain development ambitions rather than approved clinical services. CEO Westley Dang leads the company with Founder and COO Gabriel Lavella, Co-Founder and CTO Peter Ledochowitsch, and Chief Scientific Adviser Dmitry Rinberg. The company announced its change from Canaery to General Sense in January 2026. Its June 2022 seed financing raised more than $4 million, led by Breakout Ventures with participation from Dolby Family Ventures, KdT Ventures and SOSV; the exact final amount is undisclosed. DeepWork Capital also lists the company in its portfolio with a July 2023 announcement, without specifying a round or check amount. Canaery received NSF Convergence Accelerator Phase 1 R&D contract 49100424C0015 for narcotics and weapons detection: federal records show $649,984 obligated, consistent with an approximately $650,000 announcement. NSF identifies the award date as January 15, 2024, while the federal contract was signed January 23. The company's 2026 multimillion-dollar letters of intent with detection-canine operators are prospective commercial partnerships, separate from equity financing or cash receipts.

Developed polymer-based formulations that stabilize antibodies and other biologics at very high concentrations, aiming to replace lengthy intravenous infusions with rapid subcutaneous injections. Its SnapShot platform supported drug-delivery partnerships. Halozyme acquired the company in December 2025 and announced the transaction in January 2026.

Westley Dang is listed by SOSV as Partner.

Argobio Studio is a Paris-based operational biotechnology venture builder established in 2021. It sources early therapeutic projects from European academic research, co-founds and invests in companies, and embeds drug discovery, development and business expertise to advance them toward seed and Series A financing. Its programs span neuroscience, rare diseases, oncology and immunology. Its portfolio includes Elkedonia's ELK1-targeted depression program, alongside RNA, gene-therapy and protein-degradation platforms.